- Home
- VRDN vs WGS Comparison
VRDN vs WGS Comparison
Compare VRDN & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- WGS
- Stock Information
- Founded
- VRDN 2006
- WGS 2017
- Country
- VRDN United States
- WGS United States
- Employees
- VRDN N/A
- WGS N/A
- Industry
- VRDN Medical Specialities
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- VRDN Health Care
- WGS Technology
- Exchange
- VRDN Nasdaq
- WGS Nasdaq
- Market Cap
- VRDN 2.7B
- WGS 2.4B
- IPO Year
- VRDN N/A
- WGS N/A
- Fundamental
- Price
- VRDN $30.44
- WGS $145.38
- Analyst Decision
- VRDN Strong Buy
- WGS Strong Buy
- Analyst Count
- VRDN 11
- WGS 8
- Target Price
- VRDN $39.60
- WGS $130.63
- AVG Volume (30 Days)
- VRDN 1.8M
- WGS 641.8K
- Earning Date
- VRDN 11-05-2025
- WGS 10-28-2025
- Dividend Yield
- VRDN N/A
- WGS N/A
- EPS Growth
- VRDN N/A
- WGS N/A
- EPS
- VRDN N/A
- WGS 0.07
- Revenue
- VRDN $70,789,000.00
- WGS $402,190,000.00
- Revenue This Year
- VRDN N/A
- WGS $39.54
- Revenue Next Year
- VRDN $37,670.06
- WGS $22.50
- P/E Ratio
- VRDN N/A
- WGS $2,033.59
- Revenue Growth
- VRDN 23340.07
- WGS 50.50
- 52 Week Low
- VRDN $9.90
- WGS $55.17
- 52 Week High
- VRDN $30.77
- WGS $147.71
- Technical
- Relative Strength Index (RSI)
- VRDN 77.12
- WGS 64.16
- Support Level
- VRDN $28.33
- WGS $119.43
- Resistance Level
- VRDN $29.58
- WGS $147.71
- Average True Range (ATR)
- VRDN 1.32
- WGS 8.74
- MACD
- VRDN 0.18
- WGS -0.19
- Stochastic Oscillator
- VRDN 95.37
- WGS 92.03
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.